Summary
We have targeted mRNA sequences encompassing the translation initiation codon of the essential herpes simplex virus type 1 (HSV-1) IE3 gene with three kinds of anti-sense molecule. Addition of a 15mer oligodeoxyribonucleoside methylphosphonate to tissue culture cells resulted in suppression of viral replication. HSV-1 replication was also inhibited in cultured cells containing anti-sense vectors expressing transcripts complementary to the IE3 mRNA. We have also constructed a ribozyme which upon base pairing with the target 1E3 mRNA induces cleavage at the predicted GUC site. A major obstacle to anti-sense studies in animals is drug delivery of preformed anti-sense molecules to ganglionic neurons, the site of HSV latency and reactivation. We speculate as to how this may be accomplished through carrier compounds which are taken up by nerve terminals and transported by retrograde axoplasmic flow. By the same route, HSV itself may be used as an anti-sense vector.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Buzayan, J.M., Gerlach, W.L., and Bruening, G., 1986, Satellite tobacco ringspot virus RNA: a subset of the RNA sequence is sufficient for autolytic processing, Proc. Natl. Acad. Sci. USA 83:8859.
Chatis, P.A., Miller, C.H., Schrager, L.E., and Crumpacker, C.S., 1989, Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection of herpes simplex virus in a patient with acquired immunodeficiency syndrome, N. Engl. J. Med. 320:297.
Cantin, E.M., Puga, A., and Notkins, A.L., 1987, Molecular biology of herpes simplex virus latency, in: “Concepts in Viral Pathogenesis,” A.L. Notkins and M.B.A. Oldstone, eds., Springer-Verlag, New York.
Cech, T.R., and Bass, B.A., 1986, Biological catalysis by RNA, Ann Rev. Biochem. 55:599.
Coen, D.M., Kosz-Vnenchak, M., Jacobson, J.G., Leib, D.A., Bogard, C.L., Schaffer, P.A., Tyler, K.L., and Knipe, D.M., 1989, Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate, Proc. Natl. Acad. Sci. USA 86:4736.
Coleman, J.A., Green, P.J., and Inouye, M., 1984, the use of RNAs complementary to specific mRNAs to regulate the expression of individual bacterial genes, Cell 37:429.
Coleman, J.A., Hirashima, A., Inokuchi, Y., Green, P.J., and Inouye, M., 1985, A novel immune system against bacteriophage infection using complementary RNA (mic RNA), Nature 315:601.
Corey, L., and Spear, P.G., 1986, Infections with herpes simplex viruses, N. Engl. J. Med. 314:686.
Cremer, K.J., Mackett, M. Wohlenberg, C., Notkins, A.L., and Moss, B., 1985, Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice, Science 228:737.
Crumpacker, C.S., 1989, Molecular targets of antiviral therapy, N. Engl. J. Med. 321:163.
DeLuca, N.A., McCarthy, A.M., and Schaffer, P.A., 1985, Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4, J. Virol. 56:558.
Dobson, A.T., Sedarati, F., Devi-Rao, G., Flanagan, W.M., Farrell, M.J., Stevens, J.G., Wagner, E.K., and Feldman, L.T., 1989, Identification of the latency associated transcript promoter by expression of rabbit beta-globin mRNA in mouse sensory nerve ganglia latently infected with a recombinant herpes simplex virus, J. Virol. 63:3844.
Ellis, M.N., Keller, P.M., Fyfe, J.A., Martin, J.L., Rooney, J.F., Straus, S.E., NusinoffLehrman, S., and Barry, D.W., 1987, Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity, Antimicrob. Agents Chemother. 31:1117.
Erlich, K.S., Mills, J., Chatis, P., Mertz, G.J., Busch, D.F., Follansbee, S.E., Grant, R.M., and Crumpacker, C.S., 1989, Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome, N. Engl. J. Med. 320:293.
Forster, A.C., and Symons, R.H., 1987, Self-cleavage of plus and minus RNAs of a viusoid and structural model for the active sites, Cell 49:211.
Galloway, D.A., and McDougall, J.K., 1983, The oncogenic potential of herpes simplex viruses: evidence for a ‘hit and run’ mechanism, Nature 302:21.
Gontas, N.K., Harper, C., Mizutani, T., Gontas, J., 1979, Superior sensitivity of conjugates of horseradish peroxidase with wheat germ agglutinin for studies of retrograde axonal transport, J. Histochem. Cytochem. 27:728.
Harper, C.G., Gontas, J.O., Mizutani, T., and Gontas, N.K., 1980, Retrograde transport and effects of toxic ricin in the autonomic nervous system, Lab. Invest. 42:396.
Haseloff, J., and Gerlach, W.L., 1988, Simple RNA enzymes with new and highly specific endoribonuclease activities, Nature 334:585.
Hino, M., Sekizawa, T., and Openshaw, H., 1988, Ricin injection eliminates herpes simplex virus in the mouse, J. Infect. Dis. 157:1270.
Hirsch, M.C., and Schooley, R.T., 1989, Resistance to antiviral drugs: the end of innocence (editorial), N. Engl. J. Med. 320:313.
Ho, D.Y., and Mocarski, E.S., 1989, Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse, Proc. Natl. Acad. Sci. USA 86:7596.
Hutchins, C.J., Rathjen, P.D., Forster, A.C., and Symons, R.H., 1985, Self cleavage of plus and minus RNA transcripts of avocado sunblotch viroid, Nucl. Acid Res. 14:3627.
Iwasaki, Y., Yamamoto, T., Konno, H., lizuka, H., and Kudo, H., 1986, Eradication of herpes simplex virus persistence in rat trigeminal ganglia by retrograde axoplasmic transport, J. Virol. 59:242.
Izant, J.G., and Weintraub, H., 1984, Inhibition of thymidine kinase gene expression by antisense RNA: a molecular approach to genetic analysis, Cell 36:1007.
Knipe, D.M., The role of viral and cellular nuclear proteins in herpes simplex virus replication, Adv. Virus Res. 37:85.
Krol, A.R. van der, Lenting, P.E., Veenstra, J., van der Meer, I.M., Koes, R.E., Gerats, A.G.M., Mol, J.N.M., and Stuitje, A.R., 1988a, An antisense chalcone synthetase gene in transgenic plants inhibits flower pigmentation, Nature 333:866.
Krol, A.R. van der, Mol, J.N.M., and Stuitje, A.R., 1988b, Modulation of eukaryotic gene expression by complementary RNA and DNA sequences, BioTechniques 6:958.
Kulka, M., Smith, G.C., Aurelian, L., Fishelevich, R., Meade, K., Miller, P., and Ts’s, P.O.P., 1989, Site specificity of the inhibitory effects of oligonucleoside methylphosphonates complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4, Proc. Natl. Acad. Sci. USA 86:6868.
Leib, D.A., Bogard, C.L., Kosz-Vnenchak, M., Hicks, K.A., Coen, D.M., Knipe, D.M., and Schaffer, P.A., 1989a, A deletion mutant of the latency associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency, J. Virol. 63:2893.
Meignier, B., Jourdier, T.M., Norrild, B., Pereira, L., and Roizman, B., 1987, Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus, J. Infect. Dis. 155:921.
Nusinoff-Lehrman, S., Douglas, J.W., Corey, L., and Barry, D.W., 1986, Recurrent genital herpes and suppressive oral acyclovir therapy: relationship between clinical outcome and in-vitro drug sensitivity, Ann. Intern. Med. 104:786.
O’Hare, P., and Hayward, G.S., 1985, Evidence for a direct role for both the 175,000 and 110,000-molecular weight immediate early proteins of herpes simplex virus in the transactivation of delayed early promoters, J. Virol. 53:751.
Parker, A.C., Craig, J.O., Collins, P., Oliver, N., and Smith, J., 1987, Acyclovirresistant herpes simplex virus infection due to altered DNA polymerase, Lancet 2:1461.
Paterson, B.M., Roberts, B.E., and Kuff, E.L., 1977, Structural gene indentification and mapping by DNA-mRNA mediated hybrid-arrest cell-free translation, Proc. Natl. Acad. Sci. USA 74:4370.
Puga, A., and Notkins, A.L., 1987, Continued expression of a poly (A+) transcript of herpes simplex virus type 1 in trigeminal ganglia of latently infected mice, J. Virol. 61:1700.
Roizman, B., 1983, “The Herpesviruses 3”, Plenum Publishing Corporation, New York.
Roizman, B., and Sears, A.E., 1987, An inquiry into the mechanisms of herpes simplex virus latency, Ann. Rev. Microbiol. 41:543–577.
Smith, C.C., Aurelian, L., Reddy, P.M., Miller, P.S., and Ts’o, P.O.P., 1986, Antiviral effect of an oligo (nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5, Proc. Natl. Acad. Sci. USA 83:2787.
Stanberry, L.R., Bernstein, D.I., Burke, R.L., Pachl, C., and Myers, M.G., 1987, Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes, J. Infect. Dis. 155:914.
Steiner, I., Spivak, J.G., Lirette, L.P., et al., 1989, Herpes simplex virus type 1 latency-associated transcripts are evidently not essential for latent infection, EMBO Journal 8:505.
Stevens, J.G., 1989, Human herpesvirus: a consideration of the latent state, Microb. Rev. 53:318.
Stevens, J.G., Wagner, E.K., Devi-Rao, G.B., et al., 1987, RNA complementary to a herpes virus alpha gene mRNA is prominent in latently infected neurons, Science 235:1056.
Straus, S.E., Takiff, H.E., Seidlin, M., Bachrach, S., Lininger, Di Giovana, J.J., Wester, K.A., Smith, H.A., Lehrman, S.N., Creagh-Kirk, T., and Ailing, D.W., 1984, Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir, N. Engl. J. Med. 310:1545.
Spruance, S.L., Stewart, J.C., Rowe, N.H., McKeough, M.B., Wenerstrom, G., and Freeman, D.J., 1990, Treatment of recurrent herpes simplex labialis with oral acyclovir, J. Infect. Dis. 161:185.
Thoenen, H., Barde, Y.A., 1980, Physiology of nerve growth factor, Physiol. Rev. 60:1284.
Ts’o, P.O.P., Miller, P.S., Aurelian, L., Murakami, A., Agris, C., Blake, K.R., Lin, S.B., Lee, B.L., and Smith, C.C., 1987, An approach to chemotherapy based on sequence information and nucleic acid chemistry, in: “Biological Approaches to the Controlled Delivery of Drugs,” Annals N.Y. Acad. Sci. 507:220.
Uhlenbeck, O.C., 1987, A small catalytic oligoribonucleotide, Nature 328:596.
Uhlman, E., and Peyman, A., 1990, Antisense oligonucleotides: a new therapeutic principle, Chemical Reviews 90:544.
Willey, D.E., Cantin, E.M., Hill, L.R., Moss, B., Notkins, A.L., and Openshaw, H., 1988, Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection, J. Infect. Dis. 158:1382.
Willey, D.E., Williams, I., Openshaw, H., 1991, Ocular acyclovir delivery by collagen discs: a mouse model to screen anti-viral drugs, Current Eye. Res., In Press.
Wiley, R.G., Blessing, W.W., and Reis, D.J., 1982, Suicide transport: destruction of neurons by retrograde transport of ricin, abrin, and modeccin, Science 216:889.
Yamamoto, T., Iwasaki, Y., and Konno, H., 1983, Retrograde axoplasmic transport of toxic lectins is useful for transganglionic tracings of the peripheral nerve, Brain Res. 274:325.
Zamencnik, P.C., and Stephenson, M.L., 1978, Inhibition of Rous Sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide, Proc. Natl. Acad. Sci. USA 75:280.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cantin, E.M., Podsakoff, G., Willey, D.E., Openshaw, H. (1992). Antiviral Effects of Herpes Simplex Virus Specific Anti-Sense Nucleic Acids. In: Block, T.M., Jungkind, D., Crowell, R.L., Denison, M., Walsh, L.R. (eds) Innovations in Antiviral Development and the Detection of Virus Infections. Advances in Experimental Medicine and Biology, vol 312. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3462-4_14
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3462-4_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6533-4
Online ISBN: 978-1-4615-3462-4
eBook Packages: Springer Book Archive